Exploring the Potential of Neuroproteomics in Alzheimer's Disease

Author(s): Md. Sahab Uddin*, Md. Tanvir Kabir, Md. Jakaria, Eduardo Sobarzo-Sánchez, George E. Barreto, Asma Perveen, Abdul Hafeez, May N. Bin-Jumah, Mohamed M. Abdel-Daim, Ghulam M. Ashraf*

Journal Name: Current Topics in Medicinal Chemistry

Volume 20 , Issue 25 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Alzheimer's disease (AD) is progressive brain amyloidosis that damages brain regions associated with memory, thinking, behavioral and social skills. Neuropathologically, AD is characterized by intraneuronal hyperphosphorylated tau inclusions as neurofibrillary tangles (NFTs), and buildup of extracellular amyloid-beta (Aβ) peptide as senile plaques. Several biomarker tests capturing these pathologies have been developed. However, for the full clinical expression of the neurodegenerative events of AD, there exist other central molecular pathways. In terms of understanding the unidentified underlying processes for the progression and development of AD, a complete comprehension of the structure and composition of atypical aggregation of proteins is essential. Presently, to aid the prognosis, diagnosis, detection, and development of drug targets in AD, neuroproteomics is elected as one of the leading essential tools for the efficient exploratory discovery of prospective biomarker candidates estimated to play a crucial role. Therefore, the aim of this review is to present the role of neuroproteomics to analyze the complexity of AD.

Keywords: Neuroproteomics, Alzheimer's Disease, Amyloid precursor protein, Amyloid-beta, Tau, Microglia, Biomarkers.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Published on: 03 November, 2020
Page: [2263 - 2278]
Pages: 16
DOI: 10.2174/1568026620666200603112030
Price: $65

Article Metrics

PDF: 16